Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.